Cite
A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
MLA
Grünwald, Viktor, et al. “A Phase I Study of Recombinant Human Interleukin-21 (RIL-21) in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (RCC).” Acta Oncologica, vol. 50, no. 1, Jan. 2011, pp. 121–26. EBSCOhost, https://doi.org/10.3109/0284186X.2010.509104.
APA
Grünwald, V., Desar, I. M. E., Haanen, J., Fiedler, W., Mouritzen, U., Olsen, M. W. B., & van Herpen, C. M. L. (2011). A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncologica, 50(1), 121–126. https://doi.org/10.3109/0284186X.2010.509104
Chicago
Grünwald, Viktor, Ingrid M. E. Desar, John Haanen, Walter Fiedler, Ulrik Mouritzen, M. W. Brændholt Olsen, and Carla M. L. van Herpen. 2011. “A Phase I Study of Recombinant Human Interleukin-21 (RIL-21) in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (RCC).” Acta Oncologica 50 (1): 121–26. doi:10.3109/0284186X.2010.509104.